Skip to main content
Fig. 3 | EJNMMI Radiopharmacy and Chemistry

Fig. 3

From: Preclinical validations of [18F]FPyPEGCBT-c(RGDfK): a 18F-labelled RGD peptide prepared by ligation of 2-cyanobenzothiazole and 1,2-aminothiol to image angiogenesis

Fig. 3

Uptake of [18F]FPyPEGCBT-c(RGDfK) in cancer cells. U-87 MG and SKOV-3 cells were incubated with 100 kBq/mL [18F]FPyPEGCBT-c(RGDfK) for 15 to 120 min at 37 or 4 °C (a). Cells were also co-treated with 10−4 M c(RGDfV) for 1 h (b). Uptake of [18F]FPyPEGCBT-c(RGDfK) was also evaluated after 1 h of incubation with cells with selective siRNA-mediated knocked down of αV, β1, β3 or β5 integrin subunits and indicated combinations (c). Depletions were verified by immunoblotting using specific antibodies as compared to untransfected cells (Unt) and to an irrelevant depletion of luciferase (si Luc). After incubation, cells were lysed and the cell-associated radioactivity was measured in a γ-counter. Data are means ± SD of at least three independent experiments performed in quadruplicate well. Statistical differences were analysed with the one-way ANOVA test followed by Dunnett’s post hoc test as compared to 37 °C controls (b) or to si Luc (c); #p < 0.001

Back to article page